Evidence map›Paper›PMID 39678346›Full record

ArticleResearch square2024

Cross-neutralization of distant coronaviruses correlates with Spike S2-specific antibodies from immunocompetent and immunocompromised vaccinated SARS-CoV-2-infected patients.

Sara V Patel, Brooke M Leeman, Patricia J Botros, Joanna Folta, Dhiman Shahid, Anya I Rocque, Andrew S Joyal, Joseph A Vecchio, Eliza Passell, Dessie Tien and 22 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors.

Sara V PatelBiology Department, Boston College, 140 Commonwealth Avenue, Chestnut Hill, MA.
Brooke M LeemanBiology Department, Boston College, 140 Commonwealth Avenue, Chestnut Hill, MA.
Patricia J BotrosBiology Department, Boston College, 140 Commonwealth Avenue, Chestnut Hill, MA.
Joanna FoltaBiology Department, Boston College, 140 Commonwealth Avenue, Chestnut Hill, MA.
Dhiman ShahidBiology Department, Boston College, 140 Commonwealth Avenue, Chestnut Hill, MA.
Anya I RocqueBiology Department, Boston College, 140 Commonwealth Avenue, Chestnut Hill, MA.
Andrew S JoyalBiology Department, Boston College, 140 Commonwealth Avenue, Chestnut Hill, MA.
Joseph A VecchioBiology Department, Boston College, 140 Commonwealth Avenue, Chestnut Hill, MA.
Eliza PassellMassachusetts General Hospital, Harvard Medical School, Cambridge, MA, USA.
Dessie TienMassachusetts General Hospital, Harvard Medical School, Cambridge, MA, USA.
Zahra ReynoldsMassachusetts General Hospital, Harvard Medical School, Cambridge, MA, USA.
Karry SuMassachusetts General Hospital, Harvard Medical School, Cambridge, MA, USA.
Tammy D VyasMassachusetts General Hospital, Harvard Medical School, Cambridge, MA, USA.
Jatin M VyasMassachusetts General Hospital, Harvard Medical School, Cambridge, MA, USA.
Emory AbarMassachusetts General Hospital, Harvard Medical School, Cambridge, MA, USA.
Mamadou BarryMassachusetts General Hospital, Harvard Medical School, Cambridge, MA, USA.
Andrew AlexandrescuMassachusetts General Hospital, Harvard Medical School, Cambridge, MA, USA.
Zachary WallaceMassachusetts General Hospital, Harvard Medical School, Cambridge, MA, USA.
Jeffrey M DaCostaBiology Department, Boston College, 140 Commonwealth Avenue, Chestnut Hill, MA.
Manish C ChoudharyBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Trevor TamuraBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Gregory EdelsteinBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Yijia LiBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Rinki DeoBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jeffrey A SparksBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Julie BoucauRagon Institute of MGH, MIT, and Harvard, Boston, MA, USA.
Owen GloverRagon Institute of MGH, MIT, and Harvard, Boston, MA, USA.
Amy BarczakRagon Institute of MGH, MIT, and Harvard, Boston, MA, USA.
Jacob LemieuxMassachusetts General Hospital, Harvard Medical School, Cambridge, MA, USA.
Mark J SiednerMassachusetts General Hospital, Harvard Medical School, Cambridge, MA, USA.
Jonathan Z LiBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Ismael Ben FofanaBiology Department, Boston College, 140 Commonwealth Avenue, Chestnut Hill, MA.

Funding

Viral Genomics: evolution, spread, and host interactionsU19AI110818 · NIAID · BROAD INSTITUTE, INC. · PI NEAFSEY, DANIEL E · 2014 to 2024
$66.5M
VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYticsP30AR072577 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Daniel Hal Solomon · 2017 to 2026
$9.8M
Joint Biology Consortium Resource-based CenterP30AR070253 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Peter A Nigrovic, Jeffrey Andrew Sparks · 2016 to 2026
$9.4M
Rheumatoid Arthritis-Related Autoantibodies, Articular Inflammation, and RA-Associated Interstitial Lung DiseaseR01AR077607 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SPARKS, JEFFREY ANDREW · 2021 to 2025
$3.7M
Characterization of Persistent COVID-19R01AI176287 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Amy K Barczak, Jonathan Li · 2023 to 2026
$3.4M
Immunologic and Clinical Sequelae after COVID-19 in Patients with Systemic Autoimmune Rheumatic DiseasesR01AR080659 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Jeffrey Andrew Sparks · 2023 to 2026
$2.9M
NIAID NIH HHS R01 AI176287NIAID NIH HHS U19 AI110818NIAMS NIH HHS P30 AR070253NIAMS NIH HHS P30 AR072577NIAMS NIH HHS R01 AR077607NIAMS NIH HHS R01 AR080659
6 · The paper itself

Abstract

As of May 2023, the public health emergency of COVID-19 was lifted across the globe. However, SARS-CoV-2 infections continue to be recorded worldwide. This situation has been attributed to the ability of the virus to evade host immune responses including neutralizing antibody-derived Immunity. The vast majority of antibody escape mutations have been associated with the S1 subunit of the spike protein, especially the Receptor Binding Domain (RBD) but also the N-terminal Domain (NTD). The other region of the spike, the S2 subunit, is the most conserved region amongst coronaviruses. We hypothesized that S2-specific antibody responses are suboptimal in vaccinated and SARS-CoV-2 infected patients resulting in an ineffective neutralization of distant coronaviruses. Here, we analyzed S2-specific antibody responses SARS-CoV-2-infected individuals, including a mixed cohort of those with and without immunosuppression and prior vaccination. We found that S2-specific antibody responses are generally lower than S1-specific antibody responses. Furthermore, we observed in immunocompetent individuals that S1 and S2-specific antibody responses are both positively correlated with Wuhan, Omicron, SARS-CoV and W1V1-CoV pseudovirus neutralization. Among the immunocompromised patients, S1-specific antibody responses were rarely correlated with pseudovirus neutralization in contrast to S2-specific antibody responses which frequently correlated with pseudovirus neutralization. These data highlight the potential of the S2-subunit as an ideal target for induction of cross-neutralizing antibody immunity against divergent coronaviruses.

Identifiers

PMID39678346
PMCPMC11643334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.